Header Logo

Connection

Kim Steegen to HIV Reverse Transcriptase

This is a "connection" page, showing publications Kim Steegen has written about HIV Reverse Transcriptase.
Connection Strength

0,741
  1. A sensitive in-house RT-PCR genotyping system for combined detection of plasma HIV-1 and assessment of drug resistance. J Virol Methods. 2006 May; 133(2):137-45.
    View in: PubMed
    Score: 0,254
  2. Thymidine Analogue Mutations with M184V Significantly Decrease Phenotypic Susceptibility of HIV-1 Subtype C Reverse Transcriptase to Islatravir. Viruses. 2024 12 06; 16(12).
    View in: PubMed
    Score: 0,237
  3. A pragmatic approach to HIV-1 drug resistance determination in resource-limited settings by use of a novel genotyping assay targeting the reverse transcriptase-encoding region only. J Clin Microbiol. 2013 Jun; 51(6):1757-61.
    View in: PubMed
    Score: 0,105
  4. Optimization of a genotypic assay applicable to all human immunodeficiency virus type 1 protease and reverse transcriptase subtypes. J Virol Methods. 2005 Sep; 128(1-2):47-53.
    View in: PubMed
    Score: 0,062
  5. Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration. EBioMedicine. 2017 Apr; 18:225-235.
    View in: PubMed
    Score: 0,035
  6. HIV-1 phenotypic reverse transcriptase inhibitor drug resistance test interpretation is not dependent on the subtype of the virus backbone. PLoS One. 2012; 7(4):e34708.
    View in: PubMed
    Score: 0,025
  7. A synthetic HIV-1 subtype C backbone generates comparable PR and RT resistance profiles to a subtype B backbone in a recombinant virus assay. PLoS One. 2011; 6(5):e19643.
    View in: PubMed
    Score: 0,023
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.